About Chiesi Global Rare Diseases
Chiesi Global Rare Diseases is a Pharmaceuticals company, headquartered in Boston, with 1,001 - 5,000 employees and annual revenue of $100M - $500M.
Chiesi Global Rare Diseases develops products for rare diseases like Fabry Disease, Alpha-mannosidosis, Nephropathic Cystinosis, Thalassemia and LHON.
Seamless Pro Tip
Use this information to figure out if this company is an ideal customer for you.
Chiesi Global Rare Diseases Company Highlights
Phone Number
(646) 627-xxxx
Corporate Office Address
90 Canal Street
Boston, 02114
Website
Industries Served
PharmaceuticalsNumber of Employees
1,001 - 5,000 Employees
Company Revenue
$100M - $500M
Chiesi Global Rare Diseases's Tech Stack
Frequently Asked Questions About
Chiesi Global Rare Diseases
Log in or sign up to get full contact details and additional support.
What technologies does Chiesi Global Rare Diseases use?
Chiesi Global Rare Diseases uses technologies including Plesk.
How do I contact Chiesi Global Rare Diseases?
To contact Chiesi Global Rare Diseases, visit chiesiglobalrarediseases.com.
What companies are similar to Chiesi Global Rare Diseases?
Companies similar to Chiesi Global Rare Diseases include American Family Insurance, The Standard, and Guy Carpenter.
Where is Chiesi Global Rare Diseases headquartered?
Chiesi Global Rare Diseases is headquartered at 90 Canal Street, Boston.
What is the main phone number for Chiesi Global Rare Diseases?
The main phone number for Chiesi Global Rare Diseases is (646) 627-xxxx.
What is the official website for Chiesi Global Rare Diseases?
The official website for Chiesi Global Rare Diseases is chiesiglobalrarediseases.com.
What is the annual revenue of Chiesi Global Rare Diseases?
The annual revenue of Chiesi Global Rare Diseases is $100M - $500M.
How many employees does Chiesi Global Rare Diseases have?
Chiesi Global Rare Diseases has 1,001 - 5,000 employees.
What industry is Chiesi Global Rare Diseases in?
Chiesi Global Rare Diseases is in the Pharmaceuticals industry.
Last updated: November 4, 2025